Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK and Myogen sign two PAH agreements

Executive Summary

Myogen (develops small molecules for cardiovascular diseases) licensed GlaxoSmithKline ex-US commercialization rights to the Phase III pulmonary arterial hypertension (PAH) compound ambrisentan. Concurrently, GSK has licensed Myogen US marketing and distribution rights to sell its PAH drug Flolan (epoprostenol) for three years.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product or Technology Swap
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register